Safety and Allele-specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial

Overview

Journal PLoS Clin Trials

Date 2006 Nov 25

PMID 17124530

Citations 38

Authors

Mahamadou A Thera

Ogobara K Doumbo

Drissa Coulibaly

Dapa A Diallo

Issaka Sagara

Alassane Dicko

David J Diemert

D Gray Heppner Jr

V Ann Stewart

Evelina Angov

Lorraine Soisson

Amanda Leach

Kathryn Tucker

Kirsten E Lyke

Christopher V Plowe

Affiliations

Soon will be listed here.

Abstract

Objectives: The objectives were to evaluate the safety, reactogenicity, and allele-specific immunogenicity of the blood-stage malaria vaccine FMP1/AS02A in adults exposed to seasonal malaria and the impact of natural infection on vaccine-induced antibody levels.

Design: We conducted a randomized, double-blind, controlled phase I clinical trial.

Setting: Bandiagara, Mali, West Africa, is a rural town with intense seasonal transmission of Plasmodium falciparum malaria.

Participants: Forty healthy, malaria-experienced Malian adults aged 18-55 y were enrolled.

Interventions: The FMP1/AS02A malaria vaccine is a 42-kDa recombinant protein based on the carboxy-terminal end of merozoite surface protein-1 (MSP-1(42)) from the 3D7 clone of P. falciparum, adjuvanted with AS02A. The control vaccine was a killed rabies virus vaccine (Imovax). Participants were randomized to receive either FMP1/AS02A or rabies vaccine at 0, 1, and 2 mo and were followed for 1 y.

Outcome Measures: Solicited and unsolicited adverse events and allele-specific antibody responses to recombinant MSP-1(42) and its subunits derived from P. falciparum strains homologous and heterologous to the 3D7 vaccine strain were measured.

Results: Transient local pain and swelling were more common in the malaria vaccine group than in the control group (11/20 versus 3/20 and 10/20 versus 6/20, respectively). MSP-1(42) antibody levels rose during the malaria transmission season in the control group, but were significantly higher in malaria vaccine recipients after the second immunization and remained higher after the third immunization relative both to baseline and to the control group. Immunization with the malaria vaccine was followed by significant increases in antibodies recognizing three diverse MSP-1(42) alleles and their subunits.

Conclusions: FMP1/AS02A was well tolerated and highly immunogenic in adults exposed to intense seasonal malaria transmission and elicited immune responses to genetically diverse parasite clones. Anti-MSP-1(42) antibody levels followed a seasonal pattern that was significantly augmented and prolonged by the malaria vaccine.

Citing Articles

Malaria vaccines: a new era of prevention and control.

Duffy P, Gorres J, Healy S, Fried M Nat Rev Microbiol. 2024; 22(12):756-772.

PMID: 39025972 DOI: 10.1038/s41579-024-01065-7.

Inclusion of an Optimized Merozoite Surface Protein 2-Based Antigen in a Trivalent, Multistage Malaria Vaccine.

Eacret J, Parzych E, Gonzales D, Burns Jr J J Immunol. 2021; 206(8):1817-1831.

PMID: 33789984 PMC: 8026686. DOI: 10.4049/jimmunol.2000927.

Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.

Parzych E, Miura K, Long C, Burns Jr J PLoS One. 2020; 15(4):e0232355.

PMID: 32348377 PMC: 7190115. DOI: 10.1371/journal.pone.0232355.

Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.

Bailey J, Berry A, Travassos M, Ouattara A, Boudova S, Dotsey E Sci Rep. 2020; 10(1):3952.

PMID: 32127565 PMC: 7054363. DOI: 10.1038/s41598-020-60551-z.

Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02.

Berry A, Gottlieb E, Kouriba B, Diarra I, Thera M, Dutta S Malar J. 2019; 18(1):13.

PMID: 30658710 PMC: 6339315. DOI: 10.1186/s12936-019-2637-x.

References

Coulibaly D, Diallo D, Thera M, Dicko A, Guindo A, Kone A . Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg. 2003; 67(6):604-10. DOI: 10.4269/ajtmh.2002.67.604. View

Wu J, Gardner B, Murphy C, Seals J, Kensil C, Recchia J . Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol. 1992; 148(5):1519-25. View

Tanabe K, Mackay M, Goman M, Scaife J . Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J Mol Biol. 1987; 195(2):273-87. DOI: 10.1016/0022-2836(87)90649-8. View

Angov E, Aufiero B, Turgeon A, Van Handenhove M, Ockenhouse C, Kester K . Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. Mol Biochem Parasitol. 2003; 128(2):195-204. DOI: 10.1016/s0166-6851(03)00077-x. View

Darko C, Angov E, Collins W, Bergmann-Leitner E, Girouard A, Hitt S . The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun. 2004; 73(1):287-97. PMC: 538964. DOI: 10.1128/IAI.73.1.287-297.2005. View

Alonso P, Sacarlal J, Aponte J, Leach A, Macete E, Aide P . Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005; 366(9502):2012-8. DOI: 10.1016/S0140-6736(05)67669-6. View

Holder A, Guevara Patino J, Uthaipibull C, Syed S, Ling I, Blackman M . Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia. 2000; 41(1-3):409-14. View

Ockenhouse C, Angov E, Kester K, Diggs C, Soisson L, Cummings J . Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine. 2005; 24(15):3009-17. DOI: 10.1016/j.vaccine.2005.11.028. View

Diallo D, Doumbo O, Plowe C, Wellems T, Emanuel E, Hurst S . Community permission for medical research in developing countries. Clin Infect Dis. 2005; 41(2):255-9. DOI: 10.1086/430707. View

10.

Kang Y, Long C . Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Mol Biochem Parasitol. 1995; 73(1-2):103-10. DOI: 10.1016/0166-6851(95)00102-7. View

11.

Diggs C, Ballou W, MILLER L . The major merozoite surface protein as a malaria vaccine target. Parasitol Today. 1993; 9(8):300-2. DOI: 10.1016/0169-4758(93)90130-8. View

12.

Lyke K, Dicko A, Kone A, Coulibaly D, Guindo A, Cissoko Y . Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine. 2004; 22(23-24):3169-74. DOI: 10.1016/j.vaccine.2004.01.054. View

13.

Heppner Jr D, Kester K, Ockenhouse C, Tornieporth N, Ofori O, Lyon J . Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005; 23(17-18):2243-50. DOI: 10.1016/j.vaccine.2005.01.142. View

14.

Takala S, Smith D, Stine O, Coulibaly D, Thera M, Doumbo O . A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. Malar J. 2006; 5:31. PMC: 1459863. DOI: 10.1186/1475-2875-5-31. View

15.

Alonso P, Sacarlal J, Aponte J, Leach A, Macete E, Milman J . Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004; 364(9443):1411-20. DOI: 10.1016/S0140-6736(04)17223-1. View

16.

SOLTYSIK S, Bedore D, Kensil C . Adjuvant activity of QS-21 isomers. Ann N Y Acad Sci. 1993; 690:392-5. DOI: 10.1111/j.1749-6632.1993.tb44041.x. View

17.

Stoute J, Gombe J, Withers M, Siangla J, McKinney D, Onyango M . Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine. 2006; 25(1):176-84. DOI: 10.1016/j.vaccine.2005.11.037. View